In vivo: |
Lung Cancer. 2015 May;88(2):167-73. | Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC.[Pubmed: 25769883 ] | Cisplatin and Vinorelbine given intravenously is a well-established adjuvant chemotherapy regimen after surgery for early-stage NSCLC. Vinorelbine can also be administered orally. However, the efficacy of orally administrated Vinorelbine in adjuvant treatment of NSCLC is unknown. We assessed the overall survival (OS) and disease-free survival (DFS) of patients treated with adjuvant i.v. Vinorelbine or p.o. Vinorelbine, in combination with i.v. cisplatin. METHODS AND RESULTS: We reviewed two time-separated cohorts of patients referred to the Department of Oncology at Aarhus University Hospital (Denmark) from 2005 to 2012 for adjuvant chemotherapy after surgery for NSCLC. RESULTS AND Of the 265 patients included in this study, 126 patients received i.v. and 139 received p.o. Vinorelbine/cisplatin. The two groups were comparable with respect to important baseline characteristics. Median OS for all patients was 78.7 months and the median DFS was 35.7 months. No statistically significant difference in OS or DFS for patients treated with i.v. or oral Vinorelbine was detected. The DFS rates of the two groups were comparable across all variables in subgroup analysis. CONCLUSIONS: In conclusion we observed that intravenous or oral administration of Vinorelbine in combination with cisplatin after surgery for NSCLC appear equally effective in terms of overall and disease-free survival. | Expert Opin Pharmacother. 2014 Aug;15(11):1585-99. | Oral vinorelbine in the treatment of non-small-cell lung cancer.[Pubmed: 24972635] | Originally formulated as an intravenous (i.v.) agent, Vinorelbine is also currently available as an oral chemotherapeutic agent. METHODS AND RESULTS: Oral Vinorelbine has demonstrated significant activity in different settings for NSCLC, including adjuvant treatment for resected disease, concurrent chemoradiation for locally advanced NSCLC and palliative chemotherapy for recurrent/metastatic NSCLC, as part of combination schedules or as a single-agent treatment. AREAS COVERED: The authors explored the available data describing the use of oral Vinorelbine in NSCLC. PubMed articles and abstracts presented at international conferences were analysed, and relevant trials were reported and discussed. Specific settings, including the treatment of elderly and unfit patients and metronomic schedules including oral Vinorelbine, were evaluated. Available pharmacoeconomic data were also assessed. CONCLUSIONS: Oral Vinorelbine is an appealing agent, particularly as part of combination regimens containing platinum derivatives, although it can have a role as a single-agent treatment as well. Its safety profile is generally favourable and its route of administration is generally preferred by patients receiving chemotherapy. Compared to i.v. Vinorelbine and other antineoplastic agents, oral Vinorelbine has been reported to be advantageous in terms of cost savings. |
|